IASEVOLI, FELICE
 Distribuzione geografica
Continente #
AS - Asia 4.920
EU - Europa 3.745
NA - Nord America 3.471
SA - Sud America 792
AF - Africa 149
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.083
Nazione #
US - Stati Uniti d'America 3.310
SG - Singapore 2.607
RU - Federazione Russa 1.834
CN - Cina 1.180
IT - Italia 755
BR - Brasile 664
HK - Hong Kong 429
VN - Vietnam 386
DE - Germania 257
FI - Finlandia 163
NL - Olanda 132
GB - Regno Unito 106
IE - Irlanda 104
SE - Svezia 96
CA - Canada 93
UA - Ucraina 71
FR - Francia 68
CI - Costa d'Avorio 62
AR - Argentina 59
MX - Messico 50
KR - Corea 49
IN - India 48
BD - Bangladesh 42
ZA - Sudafrica 37
AT - Austria 30
ID - Indonesia 27
PL - Polonia 26
JP - Giappone 24
ES - Italia 23
TR - Turchia 20
EC - Ecuador 18
IQ - Iraq 15
CL - Cile 13
CO - Colombia 13
AE - Emirati Arabi Uniti 12
PK - Pakistan 12
HU - Ungheria 11
IS - Islanda 11
MA - Marocco 11
BE - Belgio 10
IR - Iran 10
VE - Venezuela 9
LT - Lituania 7
UZ - Uzbekistan 7
BG - Bulgaria 6
EG - Egitto 6
KE - Kenya 6
PY - Paraguay 6
AL - Albania 5
OM - Oman 5
SA - Arabia Saudita 5
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
GE - Georgia 4
HN - Honduras 4
LB - Libano 4
MY - Malesia 4
PE - Perù 4
SI - Slovenia 4
BY - Bielorussia 3
DZ - Algeria 3
ET - Etiopia 3
GA - Gabon 3
IL - Israele 3
KG - Kirghizistan 3
LA - Repubblica Popolare Democratica del Laos 3
NI - Nicaragua 3
RO - Romania 3
TH - Thailandia 3
TW - Taiwan 3
UY - Uruguay 3
AM - Armenia 2
AO - Angola 2
AU - Australia 2
BJ - Benin 2
BS - Bahamas 2
BW - Botswana 2
CH - Svizzera 2
GR - Grecia 2
JM - Giamaica 2
KZ - Kazakistan 2
MK - Macedonia 2
MN - Mongolia 2
NG - Nigeria 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
TN - Tunisia 2
AD - Andorra 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
BZ - Belize 1
CM - Camerun 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DJ - Gibuti 1
DK - Danimarca 1
GF - Guiana Francese 1
GY - Guiana 1
Totale 13.064
Città #
Singapore 1.183
Moscow 444
Hong Kong 421
Beijing 364
Chandler 354
Hefei 270
Ashburn 246
Santa Clara 211
Millbury 146
Naples 139
Ho Chi Minh City 105
Los Angeles 104
Princeton 103
Amsterdam 98
Munich 92
Dong Ket 89
Nanjing 88
San Jose 80
Wilmington 76
Des Moines 70
Redondo Beach 70
Jacksonville 67
Napoli 63
São Paulo 63
Buffalo 61
Hanoi 57
New York 57
Rome 55
Seattle 53
Boston 51
Seoul 48
Turku 45
Dallas 44
Norwalk 43
Helsinki 37
The Dalles 34
Houston 33
Nanchang 32
Ottawa 32
Brooklyn 28
Chicago 28
Shenyang 28
Nuremberg 27
Falkenstein 26
Mexico City 25
Montreal 24
Atlanta 22
Frankfurt am Main 22
Milan 22
Johannesburg 20
Changsha 19
Jiaxing 19
Rio de Janeiro 19
Biên Hòa 17
Hebei 17
Lawrence 17
Toronto 17
Da Nang 16
London 16
Orem 16
Tokyo 16
Warsaw 15
Denver 14
Stockholm 14
Woodbridge 14
Boardman 13
Haiphong 13
Poplar 13
Tianjin 13
Belo Horizonte 12
Curitiba 12
Dublin 12
Düsseldorf 12
Brasília 11
Falls Church 11
Chennai 10
Dhaka 10
Lappeenranta 10
Reykjavík 10
San Francisco 10
Vienna 10
Brussels 9
Charlotte 9
Hải Dương 9
Phoenix 9
Porto Alegre 9
Shanghai 9
Ankara 8
Bari 8
Council Bluffs 8
Guarulhos 8
Portici 8
Salvador 8
Xi'an 8
Baghdad 7
Bexley 7
Genoa 7
Ninh Bình 7
Ortona 7
Querétaro 7
Totale 6.480
Nome #
A role for D-aspartate oxidase in schizophrenia and in schizophrenia-related symptoms induced by phencyclidine in mice 140
Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: Relevance to schizophrenia 136
Neuropsychiatric disorders in Cushing's syndrome. 134
M170. GENETIC CHARACTERIZATION OF A COHORT OF PATIENTS AFFECTED BY SCHIZOPHRENIA. THE ROLE FOR RARE STRUCTURAL VARIANTS IN MODULATING TREATMENT RESISTANT ENDOPHENOTYPES: PRELIMINARY DATA 129
Current and future perspectives on the Major Depressive Disorder: Focus on the new multimodal antidepressant Vortioxetine 126
Psychological distress in serious mental illness patients during the COVID-19 outbreak and one-month mass quarantine in Italy 125
The effects of sustained COVID-19 emergency and restrictions on the mental health of subjects with serious mental illness: A prospective study 123
D-aspartate dysregulation in Ddo-/- mice modulates phencyclidine-induced gene expression changes of postsynaptic density molecules in cortex and striatum 122
Disease Severity in Treatment Resistant Schizophrenia Patients Is Mainly Affected by Negative Symptoms, Which Mediate the Effects of Cognitive Dysfunctions and Neurological Soft Signs 119
The relationship between emotional regulation and eating behaviour: a multidimensional analysis of obesity psychopathology 117
The emerging role of dopamine-glutamate interaction and of the postsynaptic density in bipolar disorder pathophysiology: Implications for treatment 116
Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: A putative link with synaptic remodeling 116
The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico-subcortical Regions. 115
Neural substrates of verbal memory impairment in schizophrenia: A multimodal connectomics study 108
Transcranial direct current stimulation for bipolar depression: systematic reviews of clinical evidence and biological underpinnings 108
Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia 108
Vein wall thickness and severity of pulmonary involvement due to sars n-cov2 virus infection 107
Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-naïve vs. antipsychotic-exposed rats 106
Assessing patient-rated vs. clinician-rated adherence to the therapy in treatment resistant schizophrenia, schizophrenia responders, and non-schizophrenia patients 106
Alexithymia, suicidal ideation, and serum lipid levels among drug-na?ve outpatients with obsessive-compulsive disorder 104
Cerebellar transcranial direct current stimulation in children with autism spectrum disorder: A pilot study on efficacy, feasibility, safety, and unexpected outcomes in tic disorder and epilepsy 104
Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones 103
Psychiatric Symptoms in Parkinson’s Disease Patients before and One Year after Subthalamic Nucleus Deep Brain Stimulation Therapy: Role of Lead Positioning and Not of Total Electrical Energy Delivered 102
Altered Patterns of Brain Glucose Metabolism Involve More Extensive and Discrete Cortical Areas in Treatment-resistant Schizophrenia Patients Compared to Responder Patients and Controls: Results From a Head-to-Head 2-[18F]-FDG-PET Study 102
Psychopathological Dimensions in Eating Disorders (E. D.) 102
Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: Translational insights in psychosis therapy and treatment resistance 102
Depression and Anxiety Symptoms "Among the Waves" of the COVID-19 Pandemic in Obsessive Compulsive Disorder and Adjustment Disorder Patients 101
Obsessive-Compulsive Aspects and Pathological Gambling in an Italian Sample 101
May second generation long-acting injectable antipsychotics be prescribed as a first-line treatment of first episode in patients with schizophrenia? An overview. 101
Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action 100
Antipsychotic and antidepressant co-treatment: effects on transcripts of inducible postsynaptic density genes possibly implicated in behavioural disorders 100
Clinical and psychopathological features associated with treatment-emergent mania in bipolar-II depressed outpatients exposed to antidepressants 100
Dopamine Dynamics and Neurobiology of Non-Response to Antipsychotics, Relevance for Treatment Resistant Schizophrenia: A Systematic Review and Critical Appraisal 99
New advances in the treatment of generalized anxiety disorder: The multimodal antidepressant vortioxetine 99
Treatment resistant schizophrenia and neurological soft signs may converge on the same pathology: Evidence from explanatory analysis on clinical, psychopathological, and cognitive variables 99
Immediate-early genes modulation by antipsychotics: Translational implications for a putative gateway to drug-induced long-term brain changes 99
Clinical evaluation of functional capacity in treatment resistant schizophrenia patients: Comparison and differences with non-resistant schizophrenia patients 99
Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study 99
Perinatal stress modulates glutamatergic functional connectivity: A post-synaptic density immediate early gene-based network analysis 98
Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies beyond Dopamine Receptor Antagonism 98
Predictors of hospitalization length of stay among re-admitted treatment-resistant Bipolar Disorder inpatients 98
Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia 98
The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials 97
Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia 97
Factor structure and reliability of the Italian adaptation of the Hypomania Check List-32, second revision (HCL-32-R2). 97
Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes. 97
The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes 97
Clinical features associated with early drop-out among outpatients with unipolar and bipolar depression 97
Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole. 96
MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine–Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective 96
Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment 96
CHD2 mutations: Only epilepsy? Description of cognitive and behavioral profile in a case with a new mutation 96
Decreased free D-aspartate levels in the blood serum of patients with schizophrenia 95
Treatment-resistant schizophrenia: Addressing white matter integrity, intracortical glutamate levels, clinical and cognitive profiles between early- and adult-onset patients 95
The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia 95
The prevalence, odds, predictors, and management of tobacco use disorder or nicotine dependence among people with severe mental illness: Systematic review and meta-analysis 94
Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions 94
Relationships between early age at onset of psychotic symptoms and treatment resistant schizophrenia 93
Glutamatergic postsynaptic density in early life stress programming: Topographic gene expression of mGlu5 receptors and Homer proteins 92
Efficacy and safety of selegiline across different psychiatric disorders: A systematic review and meta-analysis of oral and transdermal formulations 91
Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review 91
The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia 91
Fisiopatologia cellulare e molecolare 91
Dopamine receptor subtypes contribution to Homer1a induction: Insights into antipsychotic molecular action 91
Glutamatergic Postsynaptic Density Protein Dysfunctions in Synaptic Plasticity and Dendritic Spines Morphology: Relevance to Schizophrenia and Other Behavioral Disorders Pathophysiology, and Implications for Novel Therapeutic Approaches. 91
The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted 91
Striatal expression of Homer1a is affected by genotype but not dystonic phenotype of tottering mice: a model of spontaneously occurring motor disturbances 90
Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder 90
Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia 90
Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. 89
Ketamine-related expression of glutamatergic postsynaptic density genes: possible implications in psychosis 89
Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: Translational inference from a postsynaptic density immediate-early gene-based network analysis 88
Evaluation of a few discrete clinical markers may predict categorization of actively symptomatic non-acute schizophrenia patients as treatment resistant or responders: A study by ROC curve analysis and multivariate analyses 88
The Homer1 family of proteins at the crossroad of dopamine-glutamate signaling: An emerging molecular “Lego” in the pathophysiology of psychiatric disorders. A systematic review and translational insight 88
Residual effects of medications for sleep disorders on driving performance: A systematic review and network meta-analysis of randomized controlled trials 87
Predicting the Severity of Lockdown-Induced Psychiatric Symptoms with Machine Learning 86
C-reactive protein level and its relationship with suicide risk and alexithymia among newly diagnosed, drug-naïve patients with non-affective psychosis 86
Safety and tolerability of antipsychotic agents in neurodevelopmental disorders: a systematic review 86
Severity of autism-related symptoms in treatment-resistant schizophrenia: associations with cognitive performance, psychosocial functioning, and neurological soft signs - Clinical evidence and ROC analysis 85
Estimating Multimodal Structural Brain Variability in Schizophrenia Spectrum Disorders: A Worldwide ENIGMA Study 85
Addressing brain metabolic connectivity in treatment-resistant schizophrenia: a novel graph theory-driven application of 18F-FDG-PET with antipsychotic dose correction 84
Scaffolding Proteins of the Post-synaptic Density Contribute to Synaptic Plasticity by Regulating Receptor Localization and Distribution: Relevance for Neuropsychiatric Diseases 84
Predictors of Treatment Resistance Across Different Clinical Subtypes of Depression: Comparison of Unipolar vs. Bipolar Cases 84
Nutraceuticals and phytoceuticals in the treatment of schizophrenia: a systematic review and network meta-analysis “Nutra NMA SCZ” 84
The Glutamatergic Aspects of Schizophrenia Molecular Pathophysiology: Role of the Postsynaptic Density, and Implications for Treatment 83
S-Adenosyl-L-Methionine augmentation in patients with stage II treatment-resistant major depressive disorder: an open label, fixed dose, single-blind study. 83
Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma 83
The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders 82
Differential Adaptive Changes in Dopaminergic System by Acute vs. Subchronic Ketamine: Relevance for Psychosis Pathophysiology and Treatment 82
Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews 82
Prevalence and clinical features associated to bipolar disorder-migraine comorbidity: A systematic review 82
Corrigendum to “Exploring clinical phenotypes of food addiction and its distress correlates: A cross-sectional evaluation in treatment-seeking individuals with obesity” [Eating Behaviors volume 57 (April 2025), Online ahead of print, 101961] 81
Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder 81
Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment 81
Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis 80
Neurostructural subgroup in 4291 individuals with schizophrenia identified using the subtype and stage inference algorithm 80
Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. 80
Can the "connectomic way" provide a link between molecular neurobiology and phenomenological psychopathology? the case of schizophrenia 80
Cariprazine (RGH-188): A new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression? 80
Efficacia e sicurezza dell’asenapina in pazienti con episodi maniacali e misti associati a disturbo bipolare I 80
Totale 9.693
Categoria #
all - tutte 45.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.402


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021211 0 0 0 0 0 0 26 10 45 18 19 93
2021/2022719 22 1 5 15 9 53 12 30 116 71 102 283
2022/2023891 129 70 26 56 113 132 5 88 130 71 57 14
2023/2024612 30 126 54 50 29 28 27 81 20 19 95 53
2024/20254.310 194 252 9 48 122 224 487 307 260 454 1.503 450
2025/20265.415 976 722 989 700 1.567 358 103 0 0 0 0 0
Totale 13.413